Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of pharmacogenetics in the treatment of chronic hepatitis C infection.

Pharmacotherapy - 1 Feb 2014

Kawaguchi-Suzuki Marina, Frye Reginald F

Abstract excerpt

Hepatitis C virus (HCV) chronically infects 170 million people worldwide. Until recently, combination therapy with peginterferon-α (pegIFN) and ribavirin (RBV) has been the standard of care. However, for many patients, especially those infected with the most common HCV genotype 1 (HCV-1), this treatment has resulted in unsatisfactory treatment response rates. Many clinical factors, including pharmacogenetics,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferons

Share to Interleukins

Share to Pharmacogenetics

Share to Precision Medicine

Source

Identifiers

PMID: 24114761
DOI: 10.1002/phar.1349

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of pharmacogenetics in the treatment of chronic hepatitis C infection.PMID 24114761Read ↗

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsSemantic proximity Read ↗

Role of viral and host factors in interferon based therapy of hepatitis C virus infection.Semantic proximity Read ↗

Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Semantic proximity Read ↗

Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Semantic proximity Read ↗

Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?Semantic proximity Read ↗

The role of viral and host genetics in natural history and treatment of chronic HCV infection.Semantic proximity Read ↗

IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infectionSemantic proximity Read ↗

Hepatitis C pharmacogenetics: State of the art in 2010Semantic proximity Read ↗

Host genomics and HCV treatment response.Semantic proximity Read ↗

Pharmacogenetics of hepatitis CSemantic proximity Read ↗

Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?Semantic proximity Read ↗

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.